Background and objective: This study investigates the role of taxanes and immunotherapy for inoperable advanced or metastatic urothelial carcinoma in patients unable to tolerate or refractory to platinum-based regimens. We aimed to determine the safety and estimate the efficacy of a combination of avelumab and docetaxel in treating advanced or metastatic urothelial carcinoma.
Methods: This phase 1b, single-arm, open-label clinical trial involved adults with advanced or metastatic urothelial carcinoma, progressing during or after platinum-containing chemotherapy, within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, or ineligible for platinum regimens. Primary objectives were determining the maximum tolerated dose (MTD) of docetaxel with avelumab and estimating efficacy via the objective response rate (ORR). In Phase I, docetaxel (45, 60, 75 mg/m²) was combined with 10 mg/kg avelumab every 3 weeks for 6 cycles, followed by avelumab biweekly as maintenance. The expansion cohort received treatment at the MTD of 75 mg/m² docetaxel with 10 mg/kg of avelumab.
Results: Twenty-one patients with advanced or metastatic urothelial carcinoma were studied: 8 cisplatin-refractory and 13 cisplatin-ineligible. The 75 mg/m² dose of docetaxel with 10 mg/kg avelumab was safe, with 1 dose-limiting toxicity (neutropenic fever). The ORR was 52.4% (95% CI: 29.8%-74.3%). Median progression-free survival and overall survival were 14.6 months (95% CI: 2.8-15.8) and 16.6 months (95% CI: 13.2-not reached), respectively.
Conclusion: The combination of avelumab and docetaxel shows favorable safety and efficacy in treating advanced or metastatic bladder cancer.
Trial registration: Funded by Pfizer Pharmaceuticals; AVETAX; https://classic.
Clinicaltrials: gov/ct2/show/NCT03575013, NCT03575013.
Keywords: Chemoimmunotherapy; Metastatic urothelial carcinoma; Platinum intolerance; Platinum-refractory.
Copyright © 2025 Elsevier Inc. All rights reserved.